The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fucs, R.
Right arrow Articles by Nobrega, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fucs, R.
Right arrow Articles by Nobrega, A.
The Journal of Immunology, 2006, 176: 2324-2329.
Copyright © 2006 by The American Association of Immunologists

Frequency of Natural Regulatory CD4+CD25+ T Lymphocytes Determines the Outcome of Tolerance across Fully Mismatched MHC Barrier through Linked Recognition of Self and Allogeneic Stimuli1

Rita Fucs2,*, Joszilene T. Jesus*, Paulo H. N. Souza Junior*, Larissa Franco*, Mauricio Verícimo*, Maria Bellio{dagger} and Alberto Nobrega2,{dagger}

* Departamento de Immunobiologia, Instituto de Biologia, Universidade Federal Fluminense, Niteroi, Brasil; and {dagger} Departamento de Imunologia, Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
We show in this study that long-term tolerance to allogeneic skin grafts can be established in the absence of immunosuppression by the combination of the following elements: 1) augmenting the frequency of regulatory CD4+CD25+ T cells (Treg) and 2) presentation of the allogeneic stimuli through linked recognition of allo- and self-epitopes on semiallogeneic F1 APCs. BALB/c spleen cells enriched for CD4+CD25+ T lymphocytes were transferred either to BALB/c nu/nu mice or to BALB/c nu/nu previously injected with F1(BALB/c x B6.Ba) spleen cells, or else grafted with F1(BALB/c x B6.Ba) skin (chimeric BALB/c nu/nu-F1). Chimeric BALB/c nu/nu-F1 reconstituted with syngeneic CD25+-enriched spleen cells were unable to reject the previously transferred F1(BALB/c x B6.Ba) spleen cells or F1(BALB/c x B6.Ba) skin grafts, and a specific tolerance to a secondary B6 graft was obtained, with rejection of third-party CBA grafts. BALB/c nu/nu mice reconstituted only with syngeneic CD25+-enriched spleen cells rejected both B6 and CBA skin grafts. In contrast, when chimeric BALB/c nu/nu-F1 were reconstituted with spleen populations comprising normal frequencies of Treg cells, the linked recognition of allo and self resulted in breaking of self tolerance and rejection of syngeneic grafts, strongly suggesting that linked recognition works in both directions, either to establish tolerance to allo, or to break tolerance to self, the critical parameter being the relative number of Treg cells.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
In the last few years, the unequivocal description of regulatory T cells and their prominent role in the maintenance of peripheral tissue tolerance (reviewed in Refs.1, 2, 3, 4, 5) led to a conceptual reformulation of the self/nonself discrimination paradigm, classically based on the assumptions of clonal deletion or anergy of the self-reactive lymphocytes. The role of CD4+CD25+ regulatory T cells (Treg)3 in experimentally induced transplantation tolerance has been repeatedly demonstrated (5, 6, 7, 8, 9) and several protocols using Abs or drugs that temporarily inhibit the activation of alloreactive T lymphocytes result in the induction of regulatory lymphocytes, able to establish an indefinite dominant tolerance to the allogeneic graft (10). It is not yet clear whether these experimentally induced regulatory lymphocytes correspond to a distinct differentiation stage of the "conventional" Ag-specific T cell, or if they correspond to the same lineage of CD4+CD25+Foxp3+ lymphocytes which emerge from the thymus already compromised with a regulatory function ("natural" Treg cells) (11). Both possibilities were already suggested by studies using different experimental protocols. The selection of human regulatory T cells specific for a defined allopeptide from peripheral precommitted CD4+CD25+ has been reported (12), suggesting that polyclonal "natural" Treg involved in the maintenance of self tolerance may include clones cross-reactive with nonself epitopes. In contrast, alloantigen-specific CD4+CD25+ regulatory cells can develop from CD4+CD25– precursors in response to pretreatment of mice with allogeneic donor cells and anti-CD4 therapy. In this case, the generation of the Treg cells was shown to be independent from an intact thymus as well as from the expansion of CD4+CD25+ lymphocytes (13).

Experimental protocols using blocking anti-CD4/CD8 Abs were able to induce long-term tolerance to allogenic grafts (10). The allospecific tolerance state could be transferred to naive hosts injected with T lymphocytes from the tolerant animal, showing the dominant effect of regulatory T cells upon the naive T lymphocytes of the recipient animal. Furthermore, it has been demonstrated that the donor Treg recruits new Tregs from the hosts, that are able to establish allospecific tolerance if transferred to a naive recipient, a phenomenon described as "infectious tolerance" (14). It has also been shown that tolerance may be extended to other unrelated Ags when both are recognized in the same APC, linked recognition, as demonstrated for F1 grafts (15). Induction of tolerance by linked recognition could be firmly established across minor histocompatibility barriers, but much less efficiently across fully mismatched MHC. It is probable that tolerance induction by linked recognition depends on the frequency of Tregs and anti-allo-T cells participating in the immune response. By manipulating the ratio of Tregs/anti-allo-T cells it could eventually be possible to establish allogeneic tolerance across MHC barriers as well.

In the present study, we evaluated tolerance induction by linked recognition of allo- and self-epitopes presented by the same APC, in conditions where the frequencies of "natural" Treg were modified. Recipient BALB/c nu/nu mice, that have been previously injected with semiallogeneic (BALB/c x B6)F1 splenocytes or grafted with skin from (BALB/c x B6)F1, were injected with different spleen cell suspensions from BALB/c nu/+ donors: 1) CD25+-depleted cells, 2) CD25+-enriched cells, or 3) total spleen cell suspensions. The persistence of the semiallogeneic F1 spleen cells or skin graft, and the tolerance to secondary B6 skin grafts were analyzed in the three groups and we found that animals receiving CD25+-enriched spleen cells developed tolerance to fully allogeneic B6 skin grafts while rejecting third-party allografts. The results strongly suggest that "natural" Treg cells are critically involved in tolerance to allogeneic and semiallogeneic grafts, and that the manipulation of their frequency can lead to tolerance to fully allogeneic grafts, through a mechanism of linked recognition. Furthermore, a significant percentage of BALB/c nu/nu mice, that have been previously injected with semiallogeneic (BALB/c x B6)F1 spleen cells and further reconstituted with total BALB/c splenocytes (not enriched for Treg cells), rejected syngeneic skin grafts, suggesting that linked recognition of allo and self can also lead to the opposite consequence, and result in breaking of tolerance to self, depending on the relative frequency of Treg cells injected in the host.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

C57BL/6.Thy1.1+ (B6.Thy1.1+) (H-2b), BALB/c nu/+ (BALB/c), (B6.Thy1.1+ x BALB/c nu/+)F1 (F1), and CBA/J (H-2k) mice, bred in our conventional animal house (Nucleo de Animais de Laboratorio/Universidade Federal Fluminense (UFF)), were used as donors of spleen cell suspensions and tail skin for graft rejection tests. BALB/c nu/nu (H-2d) mice, used as hosts, were housed in microisolator cages and received sterilized food and water.

Cell transfers

Spleen cell suspensions were diluted in PBS after red blood cell lysis by ammonium chloride and counted in presence of trypan blue. Nylon wool-T lymphocyte-enriched spleen cells were submitted to magnetic separation: CD25+-depleted and -enriched fractions were obtained by negative and positive selections, respectively, following MACS protocol using anti-CD25 biotin (BD Biosciences/BD Pharmingen) and streptavidin-magnetic microbeads (Miltenyi Biotec-MACS). The resulting percentage of CD25+ cells in each fraction was evaluated by flow cytometry. All cell suspensions were injected i.v. into 20- to 30-day-old BALB/c nu/nu recipient mice. Cell numbers injected in each experiment and time schedule are indicated in the figure legends. T cell-depleted spleen cells from C57BL/6 were prepared by two consecutive rounds of lysis by anti-Thy1 and complement; T cell depletion was ascertained by FACS analysis and percentages of CD3+ cells were below 1%.

FACS analysis

Immunofluorescent staining and analysis of peripheral blood leukocytes and spleen cell suspensions were performed by flow cytometry (FACSCalibur; BD Biosciences), using the mAbs anti-Thy-1.1 FITC (MRC OX-7; Serotec), anti-Thy-1.2 PE (30-H12; Invitrogen Life Technologies), anti-CD4 FITC (H129.19; BD Pharmingen), anti-TCR{alpha}beta biotin (H57-597; Invitrogen Life Technologies), anti-CD25 FITC (PC61; BD Pharmingen). Streptavidin-PE (Sigma 125H8876) and Avidin-FITC (Sigma 083H4825) were used in conjunction with biotin-labeled mAbs.

Skin grafting

Full-thickness tail skins from female BALB/c, B6, F1, and CBA/J mice were grafted on the dorsum of each experimental nude mouse. Grafts were inspected two to three times per week for hair growth and integrity of the grafted skin (acceptance) or were considered to be rejected when total absence of hair growth together with numerous disruption in tissue integrity, leaving <20% of the original graft, were noted.

Statistical analysis

Statistical comparisons of the survival time of grafts were done using the nonparametric Mann-Whitney U test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Chimeric BALB/c nu/nu-F1 recipients of CD25+-enriched BALB/c lymphocytes do not eliminate F1(BALB/c x B6.Ba) spleen cells

Three groups of BALB/c nu/nu hosts, previously reconstituted with F1(BALB/c x B6.Ba) splenocytes (chimeric BALB/c nu/nu-F1), were injected with different preparations of syngeneic BALB/c nu/+ spleen cells: the first group received nonseparated, total spleen cell suspensions and the other two received the CD25+-depleted or CD25+-enriched fractions. Typically, the CD25+-depleted fraction contained <0.5% CD25+ cells and the fraction used as CD25+-enriched comprised 30–60% of CD25+ lymphocytes, corresponding to a 6- to 10-fold enrichment of the original cell suspension. The transfer of syngeneic cells obtained from the nonseparated spleen or from the CD25+-depleted fraction resulted in the complete elimination of the circulating F1 T cells from the nude hosts within the first month after injection (Fig. 1). In contrast, nude hosts receiving comparable numbers of the CD25+-enriched BALB/c spleen cells were unable to reject the semiallogeneic F1 cells. Mice of this group were studied for 11 mo after the BALB/c transfer and a high frequency of F1 T cells was still found (Fig. 1). Similar results in the three groups were obtained with different inoculums of BALB/c cells, ranging from 3 x 106 to 15 x 106 cells. The CD25+-enriched transferred T cells occasionally had a diminished initial expansion when compared with mice receiving the CD25+-depleted fraction (data not shown). However, as can be seen in Fig. 1, after 1 mo, donor-derived lymphocytes correspond to half of the T cell population in the chimeric hosts.


Figure 1
View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 1. (BALB/c x B6)F1 cells are not rejected by CD25+-enriched BALB/c spleen cells. BALB/c nu/nu hosts were injected with F1 spleen cells (Thy-1.1+/Thy-1.2+) at day 0 and further reconstituted either with CD25+-depleted (n = 5) or CD25+-enriched (n = 6) BALB/c spleen cells (Thy-1.2+), or total splenocytes (n = 20). The persistence of F1 cells in blood samples was investigated 30 days after reconstitution. Typical Thy-1.1+/Thy-1.2+ staining of peripheral blood, representative of one animal of each group, are shown. Similar results were obtained injecting cell numbers varying from 1 to 15 x 106 BALB/c cells in each group. F1 T cells were rapidly eliminated in BALB/c nu/nu hosts injected with total spleen or CD25+-depleted splenocytes (Fig. 1, upper left and lower left). Short-term and long-term persistence of F1 cells in BALB/c nu/nu hosts injected with CD25+-enriched spleen cells were demonstrated after 1 and 11 mo after reconstitution (Fig. 1, lower right and upper right).

 
Chimeric BALB/c nu/nu-F1 recipients of CD25+-enriched BALB/c lymphocytes are specifically tolerant to B6 skin grafts

The three groups of chimeric mice described above were tested for their ability to reject B6 skin grafts. Sixty days after syngeneic BALB/c spleen cell transfers, the mice were grafted with tail skin obtained from three different donors: BALB/c nu/+, C57BL/6 and CBA/J (third party allogeneic haplotype). In line with their tolerance to H-2b on (B6 x BALB/c)F1 T cells, the BALB/c nude hosts transferred with the CD25+-enriched population were also mostly unable to reject the B6 skin (Fig. 2A, F1->nu/CD25+), being statistically equivalent to animals grafted with syngeneic skin (p = 0.46, Mann-Whitney U test). Healthy grafts, with no signs of rejection crises and abundant hair growth, were observed for at least 11 mo in 80% of the animals in this group. The specificity of this tolerance was established by the complete rejection of CBA skin grafts in 100% of these hosts.


Figure 2
View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 2. CD25+-enriched BALB/c spleen cells are tolerant also to B6 skin grafts. A, BALB/c nu/nu previously injected with F1 spleen cells and further injected with CD25+-enriched BALB/c spleen cells (F1->nu/CD25+) were simultaneously grafted 1 mo later with skins from CBA ({triangleup}) (F1->nu/CD25+ (CBA)), BALB/c ({circ}) (F1->nu/CD25+ (BALB/c)), and B6 ({square}) (F1->nu/CD25+ (B6)) (n = 5), and analyzed for the kinetics of graft rejection. In the legend, the origin of the skin graft is indicated within brackets. Statistical comparisons between grafts rejections gave BALB/c x CBA, p < 0.009; BALB/c x B6, p = 0.46; B6 x CBA, p < 0.05, Mann-Whitney U test. All BALB/c nu/nu previously injected with T cell-depleted B6 splenocytes and further reconstituted with CD25+-enriched BALB/c spleen cells rejected B6 skin ({blacksquare}) (B6->nu/CD25+ (B6)). B, Kinetics of graft rejection by normal BALB/c nu/nu reconstituted with CD25+-enriched BALB/c spleen cells (nu/CD25+) (n = 6) and further grafted with skin from CBA ({triangleup}) (nu/CD25+ (CBA)), BALB/c ({circ}) (nu/CD25+ (BALB/c)), and B6 ({square}) (nu/CD25+ (B6)). Statistical comparisons between graft rejections gave: BALB/c x CBA, p < 0.04, and BALB/c x B6, p < 0.04, Mann-Whitney U test.

 
BALB/c nu/nu mice receiving only CD25+-enriched syngeneic cells, in the absence of a previously transferred F1 population, were fully able to reject allogeneic B6 skin grafts, showing that previous contact with semiallogeneic cells was necessary to induce tolerance to B6. As shown in Fig. 2B, these mice were fully able to reject CBA and B6 skin grafts (p < 0.04, Mann-Whitney U test when compared with syngeneic BALB/c graft), showing that the transferred population of CD25+-enriched T cells is functional and immunocompetent. It is important to observe that contact with allogeneic Ags on a fully mismatched combination does not lead to skin graft tolerance, as demonstrated by BALB/c nu/nu mice previously injected with T cell-depleted splenocytes from B6 donors, and reconstituted with CD25+-enriched syngeneic cells (Fig. 2A, B6->nu/CD25+). Tolerance could only be established by linked presentation of self and nonself on F1 splenocytes.

Tolerance to B6 grafts in recipients of CD25+-enriched splenocytes could also be induced by the previous grafting of the nude host with F1(BALB/c x B6.Ba) skin instead of the transfer of F1(BALB/c x B6.Ba) spleen cells (Fig. 3A, F1->nu/CD25+). Again, tolerance to B6 is strictly dependent on the presence of the alloantigen in the F1 skin graft. As shown in Fig. 3A, BALB/c nu/nu mice previously grafted with B6 and BALB/c skin and reconstituted with CD25+-enriched splenocytes rejected B6 (Fig. 3A, B6->nu/CD25+). Tolerance was dependent on the enrichment for CD25+ cells, as BALB/c nu/nu mice grafted with F1 skin and injected with total BALB/c spleen cells rejected B6 skin grafts within 40 days after grafting (Fig. 3B, F1->nu/spleen). The minimum relative enrichment for CD25+ cells needed to confer tolerance was not systematically investigated. However, in experiments described in Figs. 2 and 3, CD25+ cells varied from 30 to 60% of injected cells (Table I), representing a 6- to 10-fold enrichment, when compared with total splenocytes.


Figure 3
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 3. (BALB/c x B6)F1 skin grafts are also able to tolerize to B6 skin. BALB/c nu/nu mice were grafted with skin from (BALB/c x B6)F1, and injected 1 mo later with CD25+-enriched BALB/c spleen cells, n = 8 (A) or with nonseparated BALB/c spleen cells, n = 8 (B). After another month, all mice received skin grafts from BALB/c ({circ}) (F1->nu/CD25+ (BALB/c)) and B6 ({square}) (F1->nu/CD25+ (B6)), besides the original F1 graft ({triangledown}) (F1->nu/CD25+ (F1)). In the legend, the origin of the secondary skin graft is indicated within brackets. Eighty percent of BALB/c nu/nu mice receiving skin from B6 and BALB/c, and injected with CD25+-enriched BALB/c spleen cells (A, n = 5) rejected B6 graft ({blacksquare}) (B6->nu/CD25+ (B6)). In A, statistical comparisons between graft rejections in (F1->nu/CD25+) mice gave: BALB/c x B6, p = 0.67; BALB/c x F1, p = 0.67; and B6 x F1, p = 0.95, Mann-Whitney U test. In B, statistical comparisons between graft rejections in (F1->nu/spleen) mice gave: BALB/c x B6, p < 0.001; BALB/c x F1, p < 0.001; B6 x F1, p = 0.81, Mann-Whitney U test.

 

View this table:
[in this window]
[in a new window]
  		Table I. Phenotype and numbers of BALB/c transferred cellsa

 
Breaking tolerance to syngeneic grafts

Animals in our colony of BALB/c nu/nu hosts reconstituted with syngeneic total spleen cells behave as expected, with acute rejection (within 30 days) of allogeneic skin grafts (B6 and CBA), and tolerance to the syngeneic BALB/c skin. However, when these mice received F1(BALB/c x B6.Ba) spleen cells before the transfer of syngeneic BALB/c splenocytes, a disturbance on the tolerance to syngeneic BALB/c skin was clearly observed. Besides rejection of B6 and CBA grafts, >60% of the animals also showed a complete rejection of the syngeneic skin until 70 days after grafting (F1->nu/spleen (BALB/c)–Fig. 4A). Most of the BALB/c grafts in the remaining hosts had macroscopic signs of partial rejection, with no hair left and a marked reduction in the donor tissue present in the graft bed. The rejection of syngeneic grafts was only observed when BALB/c nu/nu were previously injected with F1 splenocytes, but not when BALB/c nu/nu were previously grafted with F1 skin (Fig. 3B). Breaking of tolerance to self could only be achieved in mice exposed to alloantigen on semiallogeneic F1 spleen cells (Fig. 4B).


Figure 4
View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 4. Linked allogeneic stimuli can lead to rejection of syngeneic skin grafts. A, BALB/c nu/nu mice were reconstituted with (BALB/c x B6)F1 splenocytes and then injected with BALB/c spleen cells, and further grafted 1 mo later with skins from BALB/c ({circ}) (F1->nu/spleen (BALB/c)), CBA ({triangleup}) (F1->nu/spleen (CBA)), and B6 ({square}) (F1->nu/spleen (B6)). These animals were analyzed for the kinetic of graft rejection, (n = 9). Control group (CTR) was BALB/c nu/nu (n = 10) reconstituted only with total spleen cells and grafted with syngeneic skin; grafts were accepted in all animals (data not shown). Statistical comparisons between graft rejections in chimeric F1->nu/spleen gave: BALB/c x B6, p = 0.72, Mann-Whitney U test. Comparison between control group and chimeric (F1->nu/spleen) mice for BALB/c syngeneic graft rejection gave p < 0.02, Mann-Whitney U test. B, BALB/c nu/nu mice were reconstituted with T cell-depleted splenocytes from B6 and then injected with BALB/c spleen cells, and further grafted 1 mo later with skins from BALB/c (•) (B6->nu/spleen (BALB/c)), CBA ({blacktriangleup}) (B6->nu/spleen (CBA)), and B6 ({blacksquare}) (B6->nu/spleen (B6)). These animals were analyzed for the kinetic of graft rejection (n = 7). Statistical comparisons between graft rejections in chimeric (B6->nu/spleen) mice gave: BALB/c x B6, p < 0.03, Mann-Whitney U test.

 
Interestingly, rejection of syngeneic BALB/c skin was also a statistically significant result occurring in >50% of mice reconstituted only with syngeneic CD25+-depleted spleen cells, even in the absence of the previous injection of F1 splenocytes (Fig. 5), corroborating the notion that pathological autoreactivity often arises from this T cell population in the absence of Treg cells (16).


Figure 5
View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 5. Rejection of syngeneic skin grafts in CD25+-depleted hosts. Normal BALB/c nu/nu reconstituted with CD25+-depleted BALB/c spleen cells (n = 11) and 1 mo after simultaneously grafted with skins from BALB/c ({circ}) (nu/CD25– (BALB/c)) and B6 ({square}) (nu/CD25– (B6)), were analyzed for the kinetic of graft rejections. Control group was BALB/c nu/nu (n = 10) reconstituted with total spleen cells and grafted with syngeneic skin, (*) (nu/spleen (BALB/c)); grafts were accepted in all those animals. Comparison between control group and BALB/c nu/nu reconstituted with CD25+-depleted BALB/c spleen cells, for syngeneic graft rejection, gave p < 0.04, Mann-Whitney U test.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The results presented here show that linked recognition of self and allogeneic Ags in the same APC may have opposite consequences depending on the relative frequency of syngeneic CD4+CD25+ cells inoculated in the recipient animal. A CD25+-enriched population was essential to obtain tolerance to the H-2b semiallogeneic F1 cells. This tolerance was specific, preventing the rejection of the circulating (BALB/c x B6)F1 cells and B6 skin grafts, but not of CBA skin grafts. The chimerism of F1 and BALB/c-derived cells in these animals was observed for 11 mo after CD25+ transfer (Fig. 1). B6 skin grafts were accepted for >12 mo after grafting, until the end of the experiment, indicating that a stable state of tolerance was established (Fig. 2A). Tolerance to B6 grafts could also be induced by the previous grafting of the nude host with F1(BALB/c x B6.Ba) skin graft instead of the transfer of F1(BALB/c x B6.Ba) spleen cells (Fig. 3A). Tolerance to B6 is strictly dependent on the linked presence of the alloantigen in F1 cells, as BALB/c nu/nu mice previously injected with T cell-depleted B6 splenocytes, or grafted with B6 skin graft, and injected with CD25+-enriched BALB/c nu/+ splenocytes, rejected the B6 graft (Figs. 2A and 3A).

We noted that the absence of linked recognition resulted in more vigorous rejection in animals previously injected with B6 splenocytes when compared with nudes previously grafted with B6 skin (Figs. 2A and 3A). In the latter, complete rejection of allogeneic grafts in some animals was observed after only 200 days. We speculate that the reduced number of fully allogeneic APCs in animals grafted only with skin may favor the indirect pathway of presentation of allogeneic Ags, by host APCs, promoting linked recognition of self and nonself. Differently, in BALB/c nu/nu injected with T cell-depleted B6 splenocytes, T cells are directly exposed to fully allogeneic stimuli in higher numbers of donor APCs, in the absence of linked recognition.

Long-term chimerism of donor lymphocytes is a hallmark of the tolerant state, as originally described by Medawar and colleagues (17). The continuous presence of semiallogeneic F1 splenic cells, as shown in Fig 1, could allow the recruitment of anti-alloregulatory T cells or promote anergy of alloreactive lymphocytes, such that chimerism could be the essential element determining tolerance in our experimental system. It is thus important to consider why semiallogeneic F1 cells are not eliminated by the CD25+-enriched spleen cells. It could be argued that the CD25+-enriched fraction would have limited expansion in the nude hosts, which might compromise their potential to reject the F1 cells. However, these animals are fully competent to reject CBA grafts. Also, the substantial frequency achieved by this donor-derived population after 1 mo (Fig. 1 and Table I) indicates that the tolerance to F1 cells in this group of CD25+-enriched hosts is not merely the effect of a lower number of lymphocytes. Moreover, as few as 0.1 x 106 CD25+-enriched spleen cells are sufficient to reconstitute nonchimeric BALB/c nude hosts leading to the rejection of allogeneic B6 and CBA skin grafts (Fig. 2B). It is important to observe that CD25+-enriched spleen cell population still contains a large percentage of CD25– T cells (a minimum of 40%), which are fully able to eliminate (BALB/c x B6)F1 cells, as shown (Fig 1 and Table I). This result suggests that the CD25– T cells present in the CD25+-enriched population do not promote the elimination of F1 cells because they are inhibited by the presence, in high frequency, of CD25+ regulatory T lymphocytes. This inhibition of CD25– T cells would probably require close cellular interactions of T CD25– and T CD25+ cells on F1 APCs, through linked recognition of self and nonself epitopes (18, 19). CD4+CD25+ Tregs may then influence the allospecific lymphocytes that recognize H-2b on the F1 APCs by aborting proliferation and effector differentiation, or driving them to anergy, or still recruiting them to a regulatory profile. Failure in obtaining tolerance when the chimeric nude recipients are reconstituted with normal BALB/c spleen cells, comprising a lower frequency of CD4+CD25+ lymphocytes, shows that enrichment for "natural" BALB/c Tregs is needed for tolerance induction.

Evidence for the inhibition of Ag-specific T lymphocytes by Tregs has been obtained in different experimental models of peripheral tolerance and it has recently been demonstrated, in vivo, that Treg cells are able to inhibit both proliferation and differentiation of CD25– T lymphocytes (20). In transplantation tolerance, Treg could be obtained by protocols which blocked acute rejection, and it has been proposed that a sustained but incomplete signaling by donor Ags, in the absence of "danger" signals, would anergize the alloreactive cells (6). Alternatively, the prevention of an initial activation of anti-alloeffector T cells may favor the indirect phase of recognition of allogeneic epitopes in host APCs, such that anti-allopeptide Treg are probably generated under the influence of natural Treg cells through linked recognition of self and allopeptides presented by the host APC. The beneficial effect of pretransplant blood transfusion on allogeneic graft acceptance was recently ascribed to the induction of CD4+CD25+ Treg cells. Although allospecificity is not always required in these protocols (21), the obligatory sharing of at least one MHC class II allele between donor and recipient in humans favors the need for linked recognition and the participation of self-reactive Treg cells for the tolerance induction (22). Also, in a model of tolerance induced by modified dendritic cells, it was shown that the coexpression of allogeneic and self epitopes and the presence of CD25+ regulatory T cells are essential to cause unresponsiveness in the indirect pathway of allorecognition (23).

As shown by Nishimura et al. (24), tolerance to the fully mismatched allograft could be obtained if the animals were reconstituted with highly purified CD4+CD25+ T cells. These results suggest that "natural" self-reactive Treg cells may have some cross-reactivity with allo-MHC+ peptides, but the frequency of cross-reactive clones seems to be low, as the presence of a small number of CD25– does not allow tolerance to be established. Here, the data we obtained show that tolerance can be established in the presence of a significant percentage of CD25– T cells, provided that the allogeneic stimuli are linked to self. It is interesting to observe that the need of linked recognition of allo and self may be less stringent in different genetic combinations of host and donor mouse strains (25). The impact of linked recognition together with CD25+ cells frequency on allotolerance may also explain the very recent results reported by Benghiat et al. (26), published while this manuscript was in preparation. They observed that F1(B6x bm12) skin is often spontaneously accepted by nonmanipulated B6 mice (50% of the recipients), in contrast to bm12 skin, which expresses only the donor MHC class II, and is rejected by all the B6 hosts studied. The tolerance to the F1 skin is apparently dependent on CD4+CD25+ Treg cells, because it is abolished by CD25+ in vivo depletion. Because in this case donor and recipient MHC difference is restricted to three amino acids, the linked presentation of their molecules in F1 grafts may be sufficient to tolerize T cell populations harboring the normal frequency of CD25+ cells.

When CD25+-depleted cells were injected in normal BALB/c nu/nu hosts, not only the allogeneic B6 graft was rejected, but also we often verified the rejection of syngeneic skin grafts (Fig. 5). Statistical analysis comparing BALB/c nu/nu reconstituted with CD25+-depleted BALB/c spleen cells with the control group of BALB/c nu/nu reconstituted with syngeneic nonseparated splenocytes gave p < 0.03, supporting the conclusion that rejection of syngeneic grafts is indeed determined by the absence of CD25+ T reg cells. This rejection adds to the general picture of systemic autoimmunity observed in immunodeficient hosts injected with CD4+CD25– T cells, characterized by multiple organ infiltration of effector autoreactive T cells (16). The inflammatory signals present in the grafted tissue may focus the autoimmune response to the syngeneic graft, leading to its rejection. These results indicate that T lymphocytes specific for self-epitopes in the skin are not deleted by thymic selection and may be peripherally controlled by Treg cells. Studies analyzing the genes expressed by T cells infiltrating tolerated allogeneic grafts, or syngeneic skin grafts, showed comparable gene expression profiles (27). Similar mechanisms may, thus, function to maintain an induced tolerance to allogeneic tissues and the natural tolerance to self-skin, both apparently depending on regulatory T cells.

More interestingly, the injection of total spleen cells in chimeric BALB/c nu/nu-F1 hosts often resulted in the rejection of syngeneic skin grafts as well (Fig. 4A). Rejection of syngeneic grafts do not occur in chimeric BALB/c nu/nu-F1 reconstituted with CD25+-enriched splenocytes (Fig. 2A). These results suggest that the frequency of Tregs is also the critical parameter controlling the outcome of autoimmunity triggered by a potent allogeneic response, through linked recognition. We speculate that a high frequency of allogeneic-specific effector lymphocytes interacting with autoreactive T cells in the same APCs, through linked interaction, as occurred in the response to F1, may revert the tolerizing influence of "natural " self-reactive regulatory cells, resulting in the activation of the anti-self lymphocytes with an effector profile. That would imply that linked recognition works in both directions, either to establish tolerance to allo, or to break tolerance to self, the critical parameter being the relative number of self-reactive Treg cells vs self-reactive effector T cells.

In conclusion, our results point to a great potential of linked recognition to control both anti-self and anti-nonself responses, that could be the basis of new strategies to control graft rejection or autoimmunity. The linked recognition of allogeneic epitopes by a high frequency of natural CD4+CD25+ cells may allow long-term or indefinite acceptance of allogeneic grafts, circumventing the need for immunosuppression.


   Acknowledgments
 
We thank Adriana Bonomo for stimulating discussions and encouragement.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, and Fundação Universitária José Bonifcio. Back

2 Address correspondence and reprint requests to Dr. Alberto Nobrega, Departamento de Imunologia, Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, predio do CCS bloco I, sala I2-051, Ilha do Fundão, CEP 21941-590, Rio de Janeiro, Brasil. E-mail address: alberton{at}acd.ufrj.br or Dr. Rita Fucs, Departamento de Imunobiologia, Instituto de Biologia, Universidade Federal Fluminense, Campos do Valonguinho, Niteroi, CEP 24210-000, Rio de Janeiro, Brasil. E-mail address: gimrita{at}vm.uff.br Back

3 Abbreviation used in this paper: Treg, CD4+CD25+ regulatory T cell. Back

Received for publication September 10, 2004. Accepted for publication November 23, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Fehérvari, Z., S. Sakaguchi. 2004. Development and function of CD25+CD4+ regulatory T cells. Curr. Opin. Immunol. 16: 203-208. [Medline]
  2. Piccirillo, C. A., E. M. Shevach. 2004. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16: 81-88. [Medline]
  3. Powrie, F., K. J. Maloy. 2003. Regulating the regulators. Science 299: 1030-1031. [Abstract/Free Full Text]
  4. Coutinho, A., H. Shohei, C. Thiago, I. Caramalho, J. Demengeot. 2001. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and "quality control" of immune responses. Immunol. Rev. 182: 89-98. [Medline]
  5. Waldmann, H., L. Graca, S. Cobbold, E. Adams, M. Tone, Y. Tone. 2004. Regulatory T cells and organ transplantation. Semin. Immunol. 16: 119-126. [Medline]
  6. Cobbold, S. P., K. F. Nolan, L. Graca, R. Castejon, A. Le Moine, M. Frewin, S. Humm, E. Adams, S. Thompson, D. Zelenika, et al 2003. Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol. Rev. 196: 109-124. [Medline]
  7. Chan, C., R. I. Lechler, A. J. T. George. 2004. Tolerance Mechanisms and recent progress. Transplant. Proc. 36: (Suppl. 2S):561S-569S. [Medline]
  8. Wood, K. J., S. Luo, A. Akl. 2004. Regulatory T cells: potential in organ transplantation. Transplantation 77: S6-S8. [Medline]
  9. Wood, K. J., S. Sakaguchi. 2003. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3: 199-210. [Medline]
  10. Waldmann, H., S. Cobbold. 2001. Regulating the immune response to transplants: a role for CD4+ regulatory cells?. Immunity 14: 399-406. [Medline]
  11. Cottrex, F., H. Groux. 2004. Specialization in tolerance: innate CD4+CD25+ versus acquired Tr1 and Th3 regulatory T cells. Transplantation 77: S12-S15. [Medline]
  12. Jiang, S., N. Camara, G. Lombardi, R. I. Lechler. 2003. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex-vivo. Blood 102: 2180-2186. [Abstract/Free Full Text]
  13. Karim, M., C. I. Kingsley, A. R. Bushell, B. S. Sawitzki, K. J. Wood. 2004. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25–CD4+ precursors in a thymus-independent process. J. Immunol. 172: 923-928. [Abstract/Free Full Text]
  14. Qin, S., S. P. Cobbold, H. Pope, E. J. Kioussis, J. Davies, H. Waldmann. 1993. "Infectious" transplantation tolerance. Science 259: 974-977. [Abstract]
  15. Davies, J. D., L. Y. W. Leong, A. Mellor, S. P. Cobbold, H. Waldmann. 1996. T cell suppression in transplantation tolerance through linked recognition. J. Immunol. 156: 3602-3607. [Abstract]
  16. Sakaguchi, S., K. Fukuma, K. Kuribayashi, T. Masuda. 1985. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a T cell subset as a possible cause of autoimmune disease. J. Exp. Med. 161: 72-87. [Abstract/Free Full Text]
  17. Billingham, R. E., L. Brent, P. B. Medawar. 1955. Acquired tolerance of skin homografts. Ann. NY Acad. Sci. 59: 409-416. [Medline]
  18. Schuhbauer, D. M., N. A. Mitchison, B. Mueller. 2000. Interaction within clusters of dendritic cells and helper T cells during initial Th1/Th2 commitment. Eur. J. Immunol. 30: 1255-1262. [Medline]
  19. Alpan, O., E. Bachelder, E. Isil, H. Arnheiter, P. Matzinger. 2004. "Educated" dendritic cells act as messengers from memory to naive T helper cells. Nat. Immunol. 5: 615-622. [Medline]
  20. Lee, M. K., IV, D. J. Moore, B. P. Jarrett, M. M. Lian, S. Deng, X. Huang, J. W. Markmann, M. Chiaccio, C. F. Barker, A. J. Caton, J. F. Markmann. 2004. Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J. Immunol. 172: 6539-6544. [Abstract/Free Full Text]
  21. Bushell, A., M. Karim, C. I. Kingsley, K.J. Wood. 2003. Pretransplant blood transfusion without additional immunotherapy generates CD25+CD4+ regulatory T cells: a potential explanation for the blood-transfusion effect. Transplantation 76: 449-455. [Medline]
  22. Roelen, D., A. Brand, F. H. J. Claas. 2004. Pretransplant blood transfusions revisited: a role for CD4+ regulatory T cells?. Transplantation 77: S26-S28. [Medline]
  23. Mirenda, V., I. Berton, J. Read, T. Cook, J. Smith, A. Dorling, R.I. Lechler. 2004. Modified dendritic cells coexpressing self and allogeneic major histocompatibility complex molecules: an efficient way to induce indirect pathway regulation. J. Am. Soc. Nephrol. 15: 987-997. [Abstract/Free Full Text]
  24. Nishimura, E., T. Sakihama, R. Setoguchi, K. Tanaka, S. Sakaguchi. 2004. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int. Immunol. 16: 1189-1201. [Abstract/Free Full Text]
  25. Graca, L., A. Le Moine, C. Y. Lin, P. Fairchild, S. Cobbold, H. Waldmann. 2004. Donor specific transplantation tolerance: the paradoxical behaviour of CD4+CD25+ T cells. Proc. Natl. Acad. Sci. USA 101: 10122-10126. [Abstract/Free Full Text]
  26. Benghiat, S., L. Graca, M. Y. Braun, S. Detienne, F. Moore, S. Buonocore, V. Flamand, H. Waldmann, M. Goldman, A. Le Moine. 2005. Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression. Transplantation 79: 648-654. [Medline]
  27. Zelenika, D., E. Adams, S. Humm, L. Graca, S. Thompson, S. P. Cobbold, H. Waldmann. 2002. Regulatory T cells overexpress a subset of Th2 gene transcripts. J. Immunol. 168: 1069-1079. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Int ImmunolHome page
G. Yang, A. Liu, Q. Xie, T. B. Guo, B. Wan, B. Zhou, and J. Z. Zhang
Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B
Int. Immunol., February 1, 2007; 19(2): 133 - 140.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fucs, R.
Right arrow Articles by Nobrega, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fucs, R.
Right arrow Articles by Nobrega, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS